The use of CD8+ cytotoxic T cells bearing antigen-specific CAR, designed to redirect T cells from cancer patients to antigen-expressing tumor cells, is the main ACT strategy for cancer therapy [146,147]. This evidence concerns the gene CD8A and cancer.